1H MRSI comparison of white matter and lesions in primary progressive and relapsing-remitting MS

Multiple Sclerosis

Volumn 6, Issue 3, 2000, Pages 148-155

  Suhy, J ^a,b,d   Rooney, W D ^a,b,c   Goodkin, D E ^a   Capizzano, A A ^a,b   Soher, B J ^a,b   Maudsley, A A ^a,b   Waubant, E ^a   Andersson, P B ^a   Weiner, M W ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BROOKHAVEN NATIONAL LABORATORY   (United States)

^d DNA Medical Center   (United States)

Author keywords

Magnetic resonance spectroscopy; Primary progressive multiple sclerosis

Indexed keywords

CREATININE; N ACETYLASPARTIC ACID; ASPARTIC ACID; CREATINE; DRUG DERIVATIVE; N-ACETYLASPARTATE; PROTON;

ADULT; ARTICLE; BRAIN INJURY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOSIS; HUMAN; MALE; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; WHITE MATTER; BRAIN; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REFERENCE VALUE;

ADULT; ASPARTIC ACID; BRAIN; CREATINE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROTONS; REFERENCE VALUES;

EID: 0033624030     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135245800701566007     Document Type: Article

References (40)

1. Thompson AJ et al. (1997) Primary Progressive multiple sclerosis. Brain 120: 1085-1096.
2. Raine C. (1994) The Dale E. McFarlin Memorial Lecture: the immunology of the multiple sclerosis lesion. Ann Neurol 36: S61-S72.
3. Trapp B et al. (1998) Axonal transection in the lesions of multiple sclerosis. New Engl J Med 338: 278-285.
4. Allen IV, McKeown SR. (1979) A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 41: 81-91.
5. Silver NC et al. (1997) Sensitivity of contrast enhanced MRI in multiple sclerosis; Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. Brain 120: 1149-1161.
6. Kidd D et al. (1997) The transverse magnetization decay characteristics of longstanding lesions and normal-appearing white matter in multiple sclerosis. J Neurol 244: 125-130.
7. Thompson AJ et al. (1991) Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 29: 53-62.
8. Filippi M et al. (1995) Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 59: 540-544.
9. Lycklama a Nijeholt GJ et al. (1998) Brain and spinal cord abnormalities in multiple sclerosis: Correlation between MRI parameters, clinical subtypes and symptoms. Brain 121: 687-697.
10. Stevenson V et al. (1998) Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 51: 234-238.
11. Giovannoni G et al. (1996) Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. J Neurol Neurosurg Psychiatry 60: 20-26.
12. McDonell G et al. (1998) Raised CSf levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis. J Neuroimmunol 85: 186-192.
13. Olerup O et al. (1989) Primary chronic progressive and relapsing remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci USA 86: 7113-7117.
14. Hillert J et al. (1992) An immunogonetic heterogeneity in multiple sclerosis. J Neurol Neurosurg Psychiatry 55: 887-890.
15. Weinshender B. (1995) The natural history of multiple sclerosis. Neurol Clin 13: 119-146.
16. Revesz T et al. (1994) A comparison of the pathology of primary and secondary progressive multiple sclerosis. Brain 117: 759-765.
17. Urenjak J, Williams SR, Gadian DG, Noble M. (1992) Specific expression of N-acetylaspartate in neurons, oligodendrocyte-type-2 astrocyte progenitors, and immature oligodendrocytes in vitro. J Neurochem 59: 55-61.
18. Chang L et al. (1998) Proton spectroscopy in myotonic dystrophy: correlations with CTG repeats [see comments]. Arch Neurol 55: 305-311.
19. Urenjak J, Williams SR, Gadian DG, Noble M. (1993) Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 13: 981-989.
20. Jagannathan NR, Desai NG, Raghunathan P. (1996) Brain metabolite changes in alcoholism: An in vivo proton magnetic resonance spectroscopy (MRS) study. Magn Reson Imaging 14: 553-557.
21. Pan JW et al. (1996) Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T. Magn Reson Med 36: 72-77.
22. Matthews PM et al. (1996) Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 119: 715-722.
23. Narayanan S et al. (1997) Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 41: 385-391.
24. Sarchielli P et al. (1999) Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal appearing white matter of multiple sclerosis. Brain 122: 513-521.
25. Husted CA et al. (1994) Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol 36: 157-165.
26. Rooney WD et al. (1997) 1H MRSI of normal appearing white matter in multiple sclerosis. Multiple Sclerosis 3: 231-237.
27. Davie CA et al. (1997) 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 63: 736-742.
28. Pan JW, Whitaker JN. (1998) Quantitation of 1H metabolites in subtypes of multiple sclerosis by spectroscopic imaging at 4.1 T. Int Soc Magn Reson Med (Abstract).
29. Presciutti O et al. (1998) 1H MRS study of normal appearing white matter in multiple sclerosis patients. Int Soc Magn Reson Med (Abstract).
30. Schumacher GA, Beebe G, Kibler RE. (1965) Problems of experimental trials of therapy in multiple sclerosis: report by the panel on evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 122: 552-568.
31. Lublin F, Reingold S. (1996) Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 46: 907-911.
32. Andersson P, Waubant E, Gee L, Goodkin DE. (1999) Multiple sclerosis progresive from onset: clinical characteristics and progression of disability. Arch Neurol (In Press).
33. Maudsley AA, Matson GB, Hugg JW, Weiner MW. (1994) Reduced phase encoding in spectroscopic imaging. Magn Reson Med 31: 645-651.
34. Maudsley AA, Lin E, Weiner MW (1992) Spectroscopic imaging display and analysis. Magn Reson Imaging 10: 471-485.
35. Soher BJ, Young K, Govindaraju V, Maudsley AA. (1998) Automated spectral analysis III: Application to in vivo proton MR spectroscopy and spectroscopic imaging. Magn Res Med 40: 822-831.
36. Pan JW, Twieg DB, Hetherington HP. (1998) Quantitative spectroscopic imaging of the human brain. Magn Reson Med 40: 363-369.
37. Benjamini Y, Hochberg Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 57: 289-300.
38. McDonell G, Hawkins SA. (1998) Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK. J Neurol Neurosurg Psychiatry 64: 451-454.
39. De Stefano N et al. (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121: 1469-1477.
40. Fu L et al. (1998) Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121: 103-113.